Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers

Next Previous
X
Search
Trial Profile

Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 136 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 08 Aug 2024 According to a Cytokinetics media release, company completed analyses of the Phase 1 study of CK-136, which met its primary objective to assess the safety, tolerability and pharmacokinetics of single and multiple doses of CK-136 in healthy participants. Due to the Companys strategic prioritization of its other clinical trial programs, further development of CK-136 has been discontinued.
    • 06 Aug 2020 According to a Cytokinetics media release, the company has completed this study with data analyses going on.
    • 06 Aug 2020 Status changed from suspended to completed, according to a Cytokinetics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top